Introduction
============

Breast cancer (BC) is the most common malignancy in women and the second leading cause of their death in the world.[@b1-ott-9-911] It is associated with the fact that the available tumor markers show low sensitivity (SE), and thus, the cancer is undetected in early stages. Considering the increasing number of cases, early diagnosis is vital, especially in the initial stages of the tumor.[@b2-ott-9-911] The substantial progress in this field has been made by screening methods that include ultrasound, computed tomography, or magnetic resonance imaging. However, in the case of small lesions, these methods are not very effective. That is why the search for new diagnostic methods that could be helpful in early cancer detection is needed.

Tumor markers are especially useful in monitoring treatment and in the detection, location, or identification of metastatic stage of cancer and early detection of its recurrence. At present, such diagnostic biomarkers in patients with BC comprise several circulating mucinous markers, including cancer antigen (CA) 15-3, carcinoembryonic antigen, and cytokeratin-19 fragments (CYFRA 21.1).[@b2-ott-9-911]--[@b4-ott-9-911] Their prognostic relevance is supported by a number of studies, but these markers have low SE and specificity (SP) in less-advanced stages of cancer, which is why they are unsuitable for screening.[@b5-ott-9-911] The new candidates for tumor markers may be cytokines, for example, vascular endothelial growth factor (VEGF)[@b6-ott-9-911] and macrophage-colony stimulating factor,[@b7-ott-9-911] matrix metalloproteinases (MMPs),[@b8-ott-9-911],[@b9-ott-9-911] and their inhibitors (tissue inhibitors of metalloproteinases \[TIMPs\]).[@b9-ott-9-911]

VEGF is considered to be an important factor in promoting angiogenesis in many pathological conditions, including malignant processes. It promotes BC progression by inducing angiogenesis and lymphangiogenesis.[@b10-ott-9-911],[@b11-ott-9-911] A high expression of VEGF and its messenger RNA have been found in BC cells.[@b11-ott-9-911],[@b12-ott-9-911]

Matrix metalloproteinase-9 (MMP-9, also known as gelatinase B) is produced by keratinocytes, monocytes, leukocytes, and a variety of malignant cells and plays an important role in BC progression.[@b13-ott-9-911]--[@b15-ott-9-911] It is involved in the degradation of the extracellular matrix that enhances breast metastasis.[@b16-ott-9-911],[@b17-ott-9-911] In tumor, MMP-9 destroys collagen (type IV) in the vascular basal membrane near the tumor cells that invade the surrounding tissues and contribute to metastasis.[@b18-ott-9-911],[@b19-ott-9-911]

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a naturally occurring glycoprotein that has been demonstrated in several types of cancer, including breast tumor.[@b20-ott-9-911]--[@b22-ott-9-911] High levels of TIMP-1 in primary tumor tissue are associated with a decreased objective response to chemotherapy[@b23-ott-9-911] and endocrine therapy in patients with metastatic BC.[@b24-ott-9-911],[@b25-ott-9-911]

In our research commenced in 2001, we have been searching for new biochemical parameters that could become biochemical markers in many types of tumors, for instance, BC,[@b26-ott-9-911],[@b27-ott-9-911] ovarian cancer,[@b28-ott-9-911],[@b29-ott-9-911] cervical cancer,[@b30-ott-9-911] endometrial cancer,[@b31-ott-9-911] lung cancer, or colon cancer.

The aim of this particular study was to determine the plasma levels of VEGF, MMP-9, its inhibitor -- TIMP-1, and CA 15-3 (comparative tumor marker) in patients with BC in relation to the control groups (consisting of patients with benign breast tumor and healthy women). These data after closer examination may be considered as a new diagnostic panel used in the diagnosis of patients with BC.

Material and methods
====================

Patients
--------

[Table 1](#t1-ott-9-911){ref-type="table"} shows the tested groups. The study included 100 women with BC diagnosed by the oncology group. The patients with BC were treated in the Department of Oncology, Medical University, Białystok, Poland. Tumor classification and staging were done in accordance with the International Union Against Cancer Tumor--Node--Metastasis classification. The BC histopathology was established in all cases with tissue biopsy of mammary tumor or after surgery from tumor cancer tissues (all patients with adenocarcinoma ductale). The pretreatment staging procedures included physical and blood examinations, mammography, mammary ultrasound scanning, breast core biopsies, and chest X-rays.

In addition, radioisotopic bone scans, examination of bone marrow aspirates, and computed tomography scans of brain and chest were performed when necessary. None of the patients had received chemo- or radiotherapy before blood sample collection.

The control groups included 50 patients with benign breast tumor and 50 healthy untreated women who underwent mammary gland examination performed by a gynecologist prior to blood sample collection. In addition, mammary ultrasound scanning was performed in all cases. The benign breast tumor histopathology was established in all cases by tissue biopsy of mammary tumor or after surgery.

The study was approved by the local Ethics Committee in Medical University of Bialystok (R-I-002/239/2014). All the patients gave their written informed consent for the examination.

Ethical declaration
-------------------

This work was conducted in accordance with the Declaration of Helsinki (1964).

Biochemical analyses
--------------------

Venous blood samples were collected from each patient into a heparin sodium tube, centrifuged 1,000 rpm for 15 minutes to obtain plasma samples, and stored at −85°C until assayed. The tested parameters were measured with the enzyme-linked immunosorbent assay (VEGF, MMP-9, TIMP-1; Quantikine Human Immunoassay, R&D Systems, Inc., Minneapolis, MN, USA) and chemiluminescent microparticle immunoassay (CA 15-3; Abbott Laboratories, Abbott Park, IL, USA) according to the manufacturer's protocols. In enzyme-linked immunosorbent assay, duplicate samples were assessed for each patient.

The intra-assay coefficient of variation of CA 15-3 is reported to be 2.2% at a mean concentration of 27.0 U/mL, standard deviation \[SD\] =0.6. VEGF is reported to be 4.5% at a mean concentration of 235 pg/mL, SD =10.6. MMP-9 is reported to be 1.9% at a mean concentration of 2.04 ng/mL, SD =0.039, and TIMP-1 is reported to be 3.9% at a mean concentration of 1.27 ng/mL, SD =0.05.

The inter-assay coefficient of variation of CA 15-3 is reported to be 2.6% at a mean concentration of 27.0 U/mL, SD =0.7. VEGF is reported to be 7.0% at a mean concentration of 250 pg/mL, SD =17.4. MMP-9 is reported to be 7.8% at a mean concentration of 2.35 ng/mL, SD =0.184, and TIMP-1 is reported to be 3.9% at a mean concentration of 1.28 ng/mL, SD =0.05.

Statistical analysis
--------------------

We defined the following diagnostic criteria: SE, SP and the predictive value of a positive (PPV) and negative (NPV) test result. Moreover, we defined the receiver-operating characteristic (ROC) curve for all the tested parameters and Spearman's rank correlation between the tested parameters and CA 15-3.

The statistical analysis was performed using STATISTICA 8.0 PL Program. The preliminary statistical analysis (chi-square test) revealed that the distribution of the levels of the tested parameters failed to follow normal distribution. Consequently, the Mann--Whitney *U*-test was used for statistical analysis between patients with cancer and control groups. Additionally, statistical analysis between the groups with different stages of BC was performed with the use of Kruskal--Wallis test and a multivariate analysis of various data with the post hoc Dwass--Steele--Crichlow--Flinger test. The data were presented as a median and a range. The Spearman's rank correlation was used in the correlation analysis. Statistically significant differences were defined as comparisons resulting in *P*\<0.05.

Diagnostic SE, SP, and the PPV and NPV test result were calculated using the following cutoff value: 95th percentile from the control group (calculated from healthy blood donors): VEGF: 121.98 pg/mL; MMP-9: 384 ng/mL; TIMP-1: 258.61 ng/mL; and CA 15-3: 23.65 U/mL. The construction of the ROC curves was performed using GraphRoc program for Windows and the area under the ROC curve (AUC) were calculated.

Results
=======

[Table 2](#t2-ott-9-911){ref-type="table"} shows the median and the range of plasma levels of the investigated parameters and CA 15-3 in the tested groups. The medians of VEGF (131.54 pg/mL) and MMP-9 (279.86 ng/mL) levels, similarly to the level of the commonly accepted tumor marker CA 15-3 (26.53 U/mL), in the total group of patients with BC were significantly higher when compared to the healthy women (*P*\<0.001, *P*=0.005, and *P*\<0.001, respectively). Additionally, the median levels of VEGF and TIMP-1 in the total BC group were statistically higher than in the group of patients with benign breast tumor (*P*=0.04, *P*\<0.001, respectively).

Also, we noticed no statistical differences between the concentrations of MMP-9 in patients with benign breast tumor and healthy controls. That is very important since higher MMP-9 levels can be observed only in patients with BC.

Similarly, we observed statistically significantly higher concentrations of VEGF in all the analyzed groups in relation to the stage of BC advancement compared to healthy women (*P*\<0.05 in all cases). Significantly higher concentrations of MMP-9 in stages III and IV (*P*=0.04 and *P*=0.05, respectively) and TIMP-1 in stage III (*P*=0.017) were also observed. We noticed similar data for CA 15-3 (*P*=0.005 -- II and *P*\<0.001 -- in III and IV stages, respectively). Moreover, plasma concentrations of the tested parameters (with the exception of MMP-9) were significantly higher in more advanced stages (III--IV) than those found in the early stages (I--II) (*P*\<0.05 in all cases).

The Spearman's rank correlation was used in the dependence analyses between the investigated parameters and CA 15-3 (data not shown). We observed a significant positive correlation between TIMP-1 with CA 15-3 concentrations in the total group of BC (*R*=0.28; *P*=0.015) and in stage I of cancer (*R*=0.52; *P*=0.014). Also, a correlation between VEGF with TIMP-1 in stage III of cancer was observed (*R*=0.62; *P*=0.004).

[Table 3](#t3-ott-9-911){ref-type="table"} shows the following diagnostic criteria: SE, SP, PPV, and NPV in patients with BC. We indicated that the SE of the tested parameters in the total cancer group was the highest for CA 15-3 (65%) and higher than for VEGF (61%), MMP-9 (37%), and TIMP-1 (17%). The combined use of the tested parameters with antigen CA 15-3 resulted in an increase in SE values (84%, 76%, and 67%, respectively). A maximum value of the total BC group was obtained for the combination of all the studied parameters (87%). Among all parameters, the highest SE in stage I of cancer was observed for VEGF (51%), in stage II of BC -- VEGF and CA 15-3 (56% both), and in stages III and IV of BC -- CA 15-3 (86% both). The combined use of the tested parameters with antigen CA 15-3 resulted in an increase in SE in every stage of BC. The highest values were obtained for the combination of VEGF or MMP-9 with CA 15-3 (III -- 100% both; IV − 96% and 91%, respectively).

The diagnostic SP for VEGF, MMP-9, TIMP-1, and CA 15-3 showed very high and equal values (for all parameters 96%).

The PPV in the total group of patients with BC was the highest for VEGF and CA 15-3 (97% both) in comparison to MMP-9 (95%) and TIMP-1 (88%). Among all the tested parameters, the highest PPV values in stage I of cancer were observed for VEGF (84%), in stage II of BC -- VEGF and CA 15-3 (86% both), and in stages III and IV of BC -- CA 15-3 (90% both). The combined use of the tested parameters with CA 15-3 resulted in a decrease in the PPV range in the combination with VEGF in all BC groups and in the combination with MMP-9 (stages I and II only). In case of a combined analysis of TIMP-1 and CA 15-3 and other stages (III and IV) in the combination of MMP-9 and CA 15-3, the increase in PPV value can be observed ([Table 3](#t3-ott-9-911){ref-type="table"}).

The predictive value of a negative test result (NPV) in the total group of BC was slightly higher for CA 15-3 (58%) than for VEGF (55%) and for MMP-9 (44%) or TIMP-1 (37%). The combined use of the tested parameters and antigen CA 15-3 resulted in an increase in the NPV in all cases, for example, with VEGF -- to 73% and with MMP-9 to 65%, but a maximum range was obtained for the combination of all parameters (75%) (total BC group). The highest NPV in stage I of cancer was observed for VEGF (80%), in stage II of BC -- VEGF and CA 15-3 (82% both), and in stages III and IV of BC -- CA 15-3 (94% both). The combined use of the tested parameters and antigen CA 15-3 resulted in an increase in the NPV value in every stage of cancer. Maximum equal ranges (100%) were obtained for the combination of VEGF and MMP-9 with CA 15-3 in stage III of BC ([Table 3](#t3-ott-9-911){ref-type="table"}).

The relationship between the diagnostic SE and SP is illustrated by the ROC curve. The AUC indicates the clinical usefulness of a tumor marker and its diagnostic power. We noticed that the VEGF area under the ROC curve (0.824) in the total group of BC was larger than the area of MMP-9 (0.678) and TIMP-1 (0.567) and was slightly lower than the AUC of CA 15-3 (0.845). Moreover, the AUCs for VEGF and MMP-9, similarly as for CA 15-3, were statistically significantly larger in comparison to AUC =0.5 (borderline of the diagnostic usefulness of the test) (*P*\<0.001, in all cases). The combined analysis of AUC for VEGF, MMP-9, and TIMP-1 with antigen CA 15-3 resulted in an increase in the areas in all cases (0.888, 0.869, and 0.847, respectively), but a maximum range in the total BC group was obtained for the combination of VEGF, MMP-9, and CA 15-3 (0.897). Additionally, the AUCs in the combined analysis of VEGF, MMP-9, and TIMP-1 with antigen CA 15-3 were statistically significantly larger in comparison to AUC =0.5 ([Table 4](#t4-ott-9-911){ref-type="table"}; [Figure 1](#f1-ott-9-911){ref-type="fig"}).

Discussion
==========

Angiogenesis, a physiological process of blood vessel formation, is crucial for tumor progression and nutrition. VEGF has been demonstrated to be a major contributor to cell proliferation, migration, and it is a potent stimulatory factor of angiogenesis. A high expression of VEGF has been found in body fluids and different kinds of tumors, for example, lung,[@b32-ott-9-911],[@b33-ott-9-911] squamous cell carcinoma of head and neck,[@b34-ott-9-911] gastric,[@b35-ott-9-911],[@b36-ott-9-911] and colon cancer.[@b37-ott-9-911]

MMPs are a family of human zinc-dependent peptidases. MMP-9 is associated with invasion, metastasis, and poor prognosis in different types of malignancies, for example, endometrial[@b38-ott-9-911] or lung[@b39-ott-9-911],[@b40-ott-9-911] cancers. The catalytic activity of MMPs can be inhibited by tissue inhibitors of metalloproteinases. A high expression of TIMPs (especially TIMP-1) has been found in esophageal,[@b41-ott-9-911] pancreatic,[@b42-ott-9-911] and gastric[@b43-ott-9-911] cancers.

According to the studied literature, high serum or plasma levels of VEGF, MMP-9, or TIMP-1 have been observed, for example, in patients with endometrial cancer,[@b38-ott-9-911],[@b44-ott-9-911]--[@b47-ott-9-911] ovarian cancer,[@b48-ott-9-911]--[@b50-ott-9-911] and BC.[@b12-ott-9-911],[@b18-ott-9-911],[@b21-ott-9-911],[@b24-ott-9-911],[@b51-ott-9-911],[@b52-ott-9-911]

In this study, the plasma levels of VEGF, MMP-9, and CA 15-3 in the total group of patients with BC were statistically significantly higher when compared with healthy women. Similar significant data were observed in the paper of Rashad et al,[@b53-ott-9-911] but these authors compared only the plasma levels of MMP-9 in patients with BC to the healthy control group. Other authors obtained identical results in ovarian cancer.[@b49-ott-9-911] In the paper of Rashad et al[@b53-ott-9-911] MMP-9 level was significantly higher in metastatic patients than nonmetastatic patients, which is different than in our results. This discrepancy can be explained by the increase in plasma level of MMP-9 from stage I to III and the decrease from stage III to IV based on the role of this parameter in angiogenesis.[@b53-ott-9-911] Comparable results for VEGF were observed in our previous study.[@b26-ott-9-911] In the publications of Ivoino et al[@b54-ott-9-911] and Findeisen et al,[@b55-ott-9-911] significantly higher serum levels of VEGF were observed in patients with BC than in healthy controls. These results are in accordance with this study and with the results obtained by other researchers, for instance, in gastric[@b41-ott-9-911] and endometrial cancer.[@b50-ott-9-911] Contrary to our results, other authors have not found significant differences in the serum levels of VEGF concentrations in early stages of BC in comparison to identical control groups.[@b56-ott-9-911] This discrepancy between the results obtained by Duranyildiz et al[@b56-ott-9-911] and our study probably resulted from a different composition and size of the group of patients compared. Furthermore, Ivoino et al[@b54-ott-9-911] observed a positive relationship between VEGF serum levels and tumor overexpression. In vivo expressions of extracellular VEGF were also significantly higher in BC tumors than in normal surrounding cells in breast tissue.[@b57-ott-9-911]

We also noticed higher plasma levels for VEGF and TIMP-1 in BC group in comparison to the group with benign lesions (statistical significance). Similar data were observed in our previous study[@b26-ott-9-911] and in the paper by Xu et al,[@b58-ott-9-911] though these authors compared only 45 patients with BC to 16 patients with benign lesions.

Significant positive Spearman's rank correlations in our study were estimated between CA 15-3 and TIMP-1 levels in the total group and stage I of patients with BC, which indicates a similarity to the commonly used tumor marker. We could not confirm our findings by other publications since no reports on the subject are available. However, in our previous study,[@b26-ott-9-911] we observed a significant positive correlation between VEGF and CA 15-3. The discrepancy between these results is probably associated with a different size of the compared groups.

In this study, the VEGF SE (61%) was the highest of all the studied parameters but lower than CA 15-3 (65%). In the study by Metwally et al,[@b52-ott-9-911] the SE of CA 15-3 (52.2%) was comparable and the highest, but the SE of VEGF (21.3%) was much lower. Those differences might be related to smaller study groups (44 patients with BC and only 15 healthy individuals in control group in the study of Metwally et al[@b52-ott-9-911]). For MMP-9, we obtained the SE of 37%, and this result was similar to the outcome obtained by Hurst et al[@b59-ott-9-911] in colorectal cancer. In case of TIMP-1, the SE obtained by Kozłowski et al[@b41-ott-9-911] in esophageal cancer (80%) was much higher than ours (17%). This discrepancy between these results is probably associated with different types of cancer and it could be the evidence for high usefulness of TIMP-1 in this type of cancer.

The SP for all the tested parameters in our study was very high and equal (96%). Similar data were observed in our previous study on BC[@b26-ott-9-911] and in ovarian cancer.[@b28-ott-9-911] The SP of VEGF was also investigated by Cao et al[@b60-ott-9-911] in case of lung cancer and was slightly lower (84.2%) than our result and the one investigated by Bunger et al[@b37-ott-9-911] in case of colon cancer. The SP obtained by them (95%) was almost the same as in our study. MMP-9 SP obtained by Hurst et al[@b59-ott-9-911] in the study on colorectal cancer was also very similar (95.8%). In case of TIMP-1, the SP obtained by Kozłowski et al[@b49-ott-9-911] in esophageal cancer (60%) was lower than in our study. The discrepancy between these results is probably associated with different types of cancer compared, and it has a higher utility only in certain types of cancer.

The PPV reflects the probability of a disease presence based on a positive result of the test. The NPV indicates the probability of disease exclusion based on a negative test result. In this investigation, VEGF and MMP-9 proved to have very high predictive values (almost the same as CA 15-3) in the total group of patients with BC and in case of VEGF, higher than CA 15-3 in stage I of BC. Almost the same results for VEGF were observed in comparison to our previous study on BC[@b26-ott-9-911] and ovarian cancer[@b28-ott-9-911] in comparison to CA 125, and this may confirm the key role of this cytokine in the carcinogenesis. Unfortunately, we could not compare our data on BC since no reports on the subject are available.

The AUC numerically describes the overall performance of a marker, with the AUC indicating a perfect SE and SP. According to this study, the ROC area of VEGF was the largest of all the tested parameters, yet slightly smaller than CA 15-3. Our results showed that the diagnostic power of the tested parameters, especially VEGF, in the group of patients with BC was almost the same as the diagnostic power of VEGF in the course of lung cancer studies conducted by Ahmed et al[@b61-ott-9-911] and Cao et al,[@b60-ott-9-911] which indicates a high importance of VEGF in those types of tumor.

Conclusion
==========

In conclusion, our present results indicate the usefulness of VEGF and MMP-9 in the diagnosis of patients with BC, especially in the combination with CA 15-3. Among the tested parameters, VEGF occurred to be the best candidate for cancer diagnosis especially in stage I of the disease and when combined with CA 15-3 as a new diagnostic panel.
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###### 

Characteristics of patients with breast cancer and control groups: benign breast tumor and healthy women

  Study group                         Number of patients
  ----------------------------------- --------------------
  Patients with breast cancer         100
   Type                               
    Adenocarcinoma ductale            100
   Median age (range), years          56 (37--78)
   Tumor stage                        
    I − T~1~N~0~M~0~                  29
    IIA − T~1~N~0~M~0~                7
    IIB − T~2~N~1~M~0~                10
    − T~3~N~0~M~0~                    7
    IIIA − T~2~N~2~M~0~               5
    − T~3~N~1~M~0~                    7
    IIIB − T~4~N~2~M~0~               6
    − T~4~N~3~M~0~                    6
    IV (metastases)                   23
   Menopausal status                  
    Premenopausal                     41
    Postmenopausal                    59
  Patients with benign breast tumor   50
   Type                               
    Adenoma                           23
    Papilloma intraductale            6
    Fibroadenoma                      16
    Mastopatia                        5
   Median age (range), years          47 (20--76)
   Menopausal status                  
    Premenopausal                     19
    Postmenopausal                    31
  Healthy women                       50
   Median age (range), years          41 (21--74)
   Menopausal status                  
    Premenopausal                     24
    Postmenopausal                    26

###### 

Plasma levels of tested parameters and CA 15-3 in patients with breast cancer and in control groups

  Groups tested                    MMP-9 (ng/mL)                                TIMP-1 (ng/mL)                                                                                                                           VEGF (pg/mL)                                                                                                                             CA 15-3 (U/mL)
  -------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Breast cancer (median, range)                                                                                                                                                                                                                                                                                                                                   
   Stage I                                                                                                                                                                                                               [\*](#tfn1-ott-9-911){ref-type="table-fn"}                                                                                               
                                   267.83                                       98.80                                                                                                                                    109.96                                                                                                                                   20.02
                                   46.81--736.92                                44.41--334.16                                                                                                                            12.98--700.02                                                                                                                            7.17--34.38
   Stage II                                                                     [\*\*](#tfn2-ott-9-911){ref-type="table-fn"}                                                                                             [\*](#tfn1-ott-9-911){ref-type="table-fn"}                                                                                               [\*](#tfn1-ott-9-911){ref-type="table-fn"}
                                   274.04                                       129.79                                                                                                                                   115.89                                                                                                                                   23.32
                                   93.65--830.12                                33.18--346.75                                                                                                                            44.47--750.66                                                                                                                            7.82--32.31
   Stage III                       [\*](#tfn1-ott-9-911){ref-type="table-fn"}   [\*](#tfn1-ott-9-911){ref-type="table-fn"}/[\*\*](#tfn2-ott-9-911){ref-type="table-fn"}/[\*\*\*](#tfn3-ott-9-911){ref-type="table-fn"}   [\*](#tfn1-ott-9-911){ref-type="table-fn"}/[\*\*](#tfn2-ott-9-911){ref-type="table-fn"}/[\*\*\*](#tfn3-ott-9-911){ref-type="table-fn"}   [\*](#tfn1-ott-9-911){ref-type="table-fn"}/[\*\*\*](#tfn3-ott-9-911){ref-type="table-fn"}
                                   360.00                                       198.23                                                                                                                                   220.48                                                                                                                                   34.12
                                   50.91--840.02                                87.05--440.69                                                                                                                            38.55--1,051.00                                                                                                                          17.50--167.87
   Stage IV                        [\*](#tfn1-ott-9-911){ref-type="table-fn"}   [\*\*](#tfn2-ott-9-911){ref-type="table-fn"}                                                                                             [\*](#tfn1-ott-9-911){ref-type="table-fn"}                                                                                               [\*](#tfn1-ott-9-911){ref-type="table-fn"}/[\*\*](#tfn2-ott-9-911){ref-type="table-fn"}/[\*\*\*](#tfn3-ott-9-911){ref-type="table-fn"}
                                   273.12                                       162.25                                                                                                                                   161.47                                                                                                                                   74.41
                                   52.83--800.09                                4.58--438.49                                                                                                                             9.02--469.90                                                                                                                             18.50--250.45
   Total group                     [\*](#tfn1-ott-9-911){ref-type="table-fn"}   [\*\*](#tfn2-ott-9-911){ref-type="table-fn"}                                                                                             [\*](#tfn1-ott-9-911){ref-type="table-fn"}/[\*\*](#tfn2-ott-9-911){ref-type="table-fn"}                                                  [\*](#tfn1-ott-9-911){ref-type="table-fn"}
                                   279.86                                       147.66                                                                                                                                   131.54                                                                                                                                   26.53
                                   46.81--840.02                                4.58--440.69                                                                                                                             9.02--1,051.00                                                                                                                           7.17--250.45
  Control groups (median, range)                                                [\*\*\*\*](#tfn4-ott-9-911){ref-type="table-fn"}                                                                                         [\*\*\*\*](#tfn4-ott-9-911){ref-type="table-fn"}                                                                                         [\*\*\*\*](#tfn4-ott-9-911){ref-type="table-fn"}
   Benign breast tumor             209.37                                       74.67                                                                                                                                    83.12                                                                                                                                    25.21
                                   36.10--840.12                                6.68--157.58                                                                                                                             9.02--970.14                                                                                                                             12.11--48.28
   Healthy women                   181.05                                       123.72                                                                                                                                   37.01                                                                                                                                    15.24
                                   65.24--421.36                                34.57--332.38                                                                                                                            4.63--180.28                                                                                                                             6.81--27.57

**Notes:**

Statistically significant when patients with BC compared with healthy women.

Statistically significant when patients with BC compared with benign breast tumor group.

Statistically significant when patients with BC stage III or IV compared with patients with BC stage I or II.

Statistically significant when patients with benign breast tumor compared with healthy women.

**Abbreviations:** CA, cancer antigen; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinase-1; VEGF, vascular endothelial growth factor; BC, breast cancer.

###### 

Diagnostic criteria of tested parameters and in combined analysis with CA 15-3 in patients with breast cancer

  Tested parameters                 Diagnostic criteria (%)   Breast cancer                   
  --------------------------------- ------------------------- --------------- ---- ----- ---- ----
  MMP-9                             SE                        26              36   46    41   37
                                    SP                        96              96   96    96   96
                                    PPV                       72              79   82    81   95
                                    NPV                       73              76   77    77   44
  TIMP-1                            SE                        6               6    41    16   17
                                    SP                        96              96   96    96   96
                                    PPV                       34              34   81    61   88
                                    NPV                       68              68   77    70   37
  VEGF                              SE                        51              56   66    71   61
                                    SP                        96              96   96    96   96
                                    PPV                       84              86   88    89   97
                                    NPV                       80              82   85    87   55
  CA 15-3                           SE                        31              56   86    86   65
                                    SP                        96              96   96    96   96
                                    PPV                       76              86   90    90   97
                                    NPV                       74              82   94    94   58
  MMP-9 + CA 15-3                   SE                        41              71   100   91   76
                                    SP                        90              90   90    90   90
                                    PPV                       68              79   84    83   95
                                    NPV                       76              87   100   96   65
  TIMP-1 + CA 15-3                  SE                        36              56   91    86   67
                                    SP                        90              90   90    90   90
                                    PPV                       65              74   83    82   94
                                    NPV                       74              81   96    93   58
  VEGF + CA 15-3                    SE                        61              76   100   96   84
                                    SP                        90              90   90    90   90
                                    PPV                       76              80   84    84   95
                                    NPV                       83              89   100   98   73
  VEGF + MMP-9 + CA 15-3            SE                        66              81   100   96   86
                                    SP                        85              85   85    85   85
                                    PPV                       69              74   78    77   92
                                    NPV                       84              89   100   98   75
  VEGF + TIMP-1 + CA 15-3           SE                        66              76   100   96   85
                                    SP                        85              85   85    85   85
                                    PPV                       69              72   77    78   93
                                    NPV                       84              88   100   98   73
  MMP-9 + TIMP-1 + VEGF + CA 15-3   SE                        71              81   100   96   87
                                    SP                        80              80   80    80   80
                                    PPV                       65              68   72    71   91
                                    NPV                       85              90   100   98   75

**Abbreviations:** CA, cancer antigen; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinase-1; VEGF, vascular endothelial growth factor; PPV, positive predictive value; NPV, negative predictive value; SE, sensitivity; SP, Specificity.

###### 

Diagnostic criteria of ROC curve for tested parameters and CA 15-3

  Tested parameters                 ROC criteria in breast cancer (total group)                           
  --------------------------------- --------------------------------------------- -------- -------------- ---------
  VEGF                              0.824                                         0.0401   0.743--0.901   \<0.001
  MMP-9                             0.678                                         0.0497   0.538--0.778   \<0.001
  TIMP-1                            0.567                                         0.0547   0.462--0.687   0.1952
  CA 15-3                           0.845                                         0.0365   0.776--0.919   \<0.001
  VEGF + CA 15-3                    0.888                                         0.0314   0.827--0.950   \<0.001
  MMP-9 + CA 15-3                   0.869                                         0.0337   0.799--0.932   \<0.001
  TIMP-1 + CA 15-3                  0.847                                         0.0363   0.777--0.920   \<0.001
  VEGF + MMP-9 + CA 15-3            0.897                                         0.0296   0.839--0.955   \<0.001
  VEGF + TIMP-1 + CA 15-3           0.889                                         0.0313   0.828--0.950   \<0.001
  VEGF + MMP-9 + TIMP-1 + CA 15-3   0.897                                         0.0297   0.839--0.955   \<0.001

**Note:** *P* -- statistically significantly larger AUCs compared to AUC =0.5.

**Abbreviations:** ROC, receiver-operating characteristics; CA, cancer antigen; AUC, area under the ROC curve; SE, standard error; CI, confidence interval; VEGF, vascular endothelial growth factor; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinase-1.
